Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to unlock secrets of CMV in transplant patients

NCT ID NCT05701228

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults receiving a kidney, lung, liver, or heart transplant. It will collect blood and tissue samples to learn how the body responds to CMV, a common virus that can cause serious problems after transplant. The goal is to better understand the virus and improve future care. No new treatments are being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

552 people

The number who actually took part.

Started

Jun 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort 1 will include 450 patients at the time of transplantation: Kidney: 6 groups : 50 R+ATG no mTORi, 30 R+ATG mTORi, 50 R+ no ATG no mTORi, 30 R+ no ATG mTORi, 50 D+R- no mTORi, 30 D+R- mTORi Lung: 3 groups of 20 patients R+ ATG,R+ no ATG, D+R- Heart: 3 groups of 30 patients R+ ATG, R+ no ATG, D+R- Liver: 3 groups of 20 patients R+ ATG, R+ no ATG, D+R- Cohort 2 will include 150 patients at the time of the infection: Approximatively 75 patients are expected to roll-over from the cohort of solid-organ transplant recipients included at day 0 of transplantation (cohort 1). Additional 75 patients developing a CMV infection will be also included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

A cohort 1 of solid-organ transplant recipients at day 0 of transplantation will be included: * Consecutive patients meeting the following inclusion criteria will be included: * Men and women, * Age \>= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft, * written informed consent obtained from subject, * ability to understand and give their written consent, * affiliated to health insurance. * Exclusion criteria would be: * D-R- recipients, * participant unable or unwilling to comply with study procedures, * subjects who are legally detained in an official institution. A cohort 2 of solid-organ transplant recipients at day 0 of infection: * Consecutive patients meeting the following inclusion criteria will be included: * Men and women, * Age \>= 18 years receiving a (living or deceased donor) kidney, lung, liver, and heart allograft * written informed consent obtained from subject, * ability to understand and give their written consent, * affiliated to health insurance, * post-transplant CMV infection episode. * Exclusion criteria would be: * D-R- recipients, * participant unable or unwilling to comply with study procedures, * subjects who are legally detained in an official institution.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus infections Solid organ transplantation

Contacts and locations

Locations

  • Hopitel Pellegrin

    Bordeaux, 33076, France

  • Hôpital Edouard Hériot

    Lyon, 69003, France

  • Hôpital Foch

    Suresnes, 92150, France

  • Hôpital LA PITIE SALPETRIERE

    Paris, 75013, France

  • Hôpital Necker

    Paris, 75015, France

  • Hôpital Paul Brousse

    Villejuif, 94804, France

  • Hôpital Rangueil

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.